Woodline Partners LP Seelos Therapeutics, Inc. Transaction History

Woodline Partners LP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$0.16 - $1.64 $24,093 - $246,959	150,585 Added 26.23%	724,571 $130,000
Q2 2023 Aug 14, 2023	BUY	$0.66 - $1.22 $378,830 - $700,262	573,986 New	573,986 $688,000
Q3 2022 Nov 14, 2022	SELL	$0.65 - $1.41 $298,798 - $648,162	-459,690 Reduced 39.66%	699,266 $720,000
Q2 2022 Aug 15, 2022	SELL	$0.51 - $0.93 $838,579 - $1.53 Million	-1,644,274 Reduced 58.66%	1,158,956 $788,000
Q1 2022 May 16, 2022	SELL	$0.84 - $1.71 $1.04 Million - $2.13 Million	-1,244,001 Reduced 30.74%	2,803,230 $2.35 Million

Q4 2021 Feb 14, 2022	SELL	$1.59 - $2.38 $528,142 - $790,552	-332,165 Reduced 7.58%	4,047,231 $6.6 Million
Q3 2021 Nov 15, 2021	BUY	$1.69 - $2.89 $2.26 Million - $3.86 Million	1,334,964 Added 43.85%	4,379,396 $10.6 Million
Q2 2021 Aug 16, 2021	BUY	$2.64 - $6.32 $6.16 Million - $14.7 Million	2,333,194 Added 328.05%	3,044,432 $8.04 Million
Q1 2021 May 17, 2021	BUY	$1.35 - $4.99 $960,171 - $3.55 Million	711,238 New	711,238 $3.55 Million

40.5K

Ticker SEEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 106,691,000
Market Cap $59.7M
Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in...

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

Stay updated on Woodline Partners LP with notifications on news.